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Open acAbstract Aim: The purpose of this multicenter cohort study was to evaluate whether a dif-
ferentiated treatment of primary rectal cancer based on magnetic resonance imaging (MRI)
can reduce the number of incomplete resections and local recurrences and improve recur-
rence-free and overall survival.
Methods: From February 2003 until January 2008, 296 patients with rectal cancer underwent
preoperative MRI using a lymph node speciﬁc contrast agent to predict circumferential resec-
tion margin (CRM), T- and N-stage. Based on expert reading of the MRI, patients were strat-
iﬁed in: (a) low risk for local recurrence (CRM > 2 mm and N0 status), (b) intermediate risk
and (c) high risk (close/involved CRM, N2 status or distal tumours). Mainly based on this
MRI risk assessment patients were treated with (a) surgery only (TME or local excision),
(b) preoperative 5  5 Gy + TME and (c) a long course of chemoradiation therapy followed
by surgery after a 6–8 week interval.
Results: Overall 228 patients underwent treatment with curative intent: 49 with surgery only,
86 with 5  5 Gy and surgery and 93 with chemoradiation and surgery. The number of com-
plete resections (margin > 1 mm) was 218 (95.6%). At a median follow-up of 41 months the06
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2312 S.M.E. Engelen et al. / European Journal of Cancer 49 (2013) 2311–2320three-year local recurrence rate, disease-free survival rate and overall survival rate is 2.2%,
80% and 84.5%, respectively.
Conclusion: With a differentiated multimodality treatment based on dedicated preoperative
MR imaging, local recurrence is no longer the main problem in rectal cancer treatment.
The new challenges are early diagnosis and treatment, reducing morbidity of treatment and
preferably prevention of metastatic disease.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
In the past decades studies have shown that the risk
for recurrence after resection of rectal cancer is substan-
tially reduced with the surgical technique of the total
mesorectal excision (TME). In this technique, popular-
ised by Heald, the tumour is removed as a complete
package including the surrounding mesorectal fat and
lymph nodes.1 Additionally, neoadjuvant (chemo)radia-
tion has improved local control and, in some studies,
survival.2–5 Intensifying treatment of rectal cancer how-
ever is at the expense of treatment-induced morbidity
and even mortality. Therefore, individualisation of
treatment taking into account characteristics such as
age, co-morbidity, stage and location of the tumour
might provide an optimal balance between minimising
treatment related morbidity and best oncological out-
come. Until now, there is however no deﬁnite evidence
that the outcome is better than applying a single stan-
dard treatment for all patients. Subgroup analyses
within the large randomised trials can provide clues as
to what factors can be used to guide treatment decisions
for individual patients. In most of the trials patients with
stage I disease (T1-2N0) have a negligible risk for local
recurrence, and therefore do not need preoperative irra-
diation.6 On the other hand, in patients with a combina-
tion of unfavourable characteristics like a tumour
extending into the mesorectal fascia, positive lymph
nodes and a very distal location, a short course of preop-
erative radiation and immediate surgery does not pro-
vide enough protection against local recurrence, and a
long course of preoperative chemoradiation (CRT) is
required.2,3,6
Reliable preoperative imaging is essential for a diﬀer-
entiated treatment according to risk factors for local
recurrence. Although endorectal ultrasound is good in
assessing the extent of the primary tumour in small
lesions,7 magnetic resonance imaging (MRI) has repeat-
edly shown to provide the best information on the rela-
tion of the tumour to the mesorectal fascia.8–12
Assessing nodal involvement however has been subopti-
mal, and until now all three imaging modalities (endo-
scopic ultrasound, computed tomography (CT) and
MRI) lack suﬃcient accuracy for clinical decision-mak-
ing.13 MRI studies with lymph node-speciﬁc contrast
agents have shown promising results for the prediction
of nodal involvement.14,15 This would enable MRI toassess the two most important risk factors for local
recurrence: relation of the tumour to the mesorectal fas-
cia and nodal stage.
The primary aim of our prospective cohort study was
to assess the outcome as deﬁned by the number of
complete resections of a diﬀerentiated treatment proto-
col for rectal cancer, based on MRI. The secondary
aim was the assessment of long-term outcome as deﬁned
by three-year local recurrence, disease-free and overall
survival, compared to the data of the Dutch TME trial.
2. Patients and methods
2.1. Patients
Between February 2003 and January 2008, a prospec-
tive multicentre cohort study was performed in patients
with primary rectal cancer in whom a diﬀerentiated
treatment protocol was primarily based on MRI. In
February 2003 the study started as a single centre pilot
study at the Maastricht University Medical Centre,
and was continued as a multicentre study from Decem-
ber 2005 onwards (n = 117). Three regional hospitals
joined the study: Laurentius Hospital Roermond (start
of inclusion: 12–2005, n = 38), St. Jans Hospital Weert
(start of inclusion: 12–2005, n = 17) and VieCuri Medi-
cal Center Venlo (start of inclusion: 02–2006, n = 58).
Institutional review board approval was obtained for
all hospitals. All patients gave a written informed
consent.
2.1.1. Inclusion criteria
Histologically proven adenocarcinoma of the rectum.
2.1.2. Exclusion criteria
Patients were excluded from the study if they had
locally recurrent rectal cancer, were pregnant, were
younger than 18 years, had a contra-indication for
MR imaging (pacemaker, neurostimulator, insulin
pump and certain vascular clips (e.g. used in brain sur-
gery), cochlear implants, metal fragments in the eye or
any other metal implant not securely ﬁxed or electronic
device), or did not give informed consent for participa-
tion. For the present analyses that include long-term
outcome, patients who received palliative treatment or
who had a previous or coexisting malignancy were
excluded.
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All patients underwent a pelvic MRI with standard
T2W TSE sequences in three orthogonal directions (sag-
ittal, axial and coronal) and an axial 3D T1W gradient
echo (GRE) sequence. For nodal staging an axial
T2*W GRE was performed with ultrasmall super para-
magnetic iron oxide (USPIO), a lymph node speciﬁc
contrast agent. The USPIO MR contrast agent (Sine-
rem, Guerbet Laboratories, Roissy, France) consists of
low molecular weight iron oxide coated with dextran.
Sinerem was administered at a dose of 2.6 mg Fe/kg
by slow intravenous infusion during a period of
45 min, 24–36 h before the MRI scan. No side-eﬀects
were recorded during or after infusion. Imaging was per-
formed on a 1.0/1.5 T MR scanner. Patients did not
receive bowel or other preparation. Total scan time
was approximately 40 min.
2.5. Image evaluation
All MRI scans were read by both a local radiologist
and an expert reader, and evaluated for T-stage, N-
stage, involvement of the mesorectal fascia and height
of the tumour. USPIO images were read for the predic-
tion of nodal status by predeﬁned criteria based on con-
trast uptake, size and shape.16,17
2.6. Treatment stratiﬁcation and strategy
In a multidisciplinary meeting the treatment plan for
each individual patient was determined based on the
clinical information, MR imaging of local disease and
imaging for distant disease. Patients with widespread
metastatic disease and/or a very poor general condition
that precluded major surgery were considered for palli-
ative treatment only, and are excluded from the present
analysis. For the other patients the tumour wasFig. 1. MRI treatment sclassiﬁed on the basis of the MR images patients as
‘low’, ‘intermediate’ and ‘high’ risk for local recurrence.
Low risk was deﬁned as T1-2N0 or T3N0 with a wide
circumferential resection margin (CRM) (>2 mm) when
localised in the proximal rectum. The deﬁnition of a
wide CRM was chosen on the basis of the widely recog-
nised 1 mm at histology with an additional 1 mm safety
margin to compensate for small MR measurement
errors. High risk was deﬁned as tumours with circumfer-
ential resection margin <2 mm, distal tumours (i.e.
<5 cm from the anal verge) or N2 status. All other
tumours were considered as intermediate risk (see
Fig. 1). Generally, low risk tumours were treated with
surgery only, intermediate risk tumours were treated
with 5  5 Gy (Gray) preoperative radiotherapy fol-
lowed by surgery within 1 week after the last radiation
fraction, and high risk tumours were treated with a long
course of CRT and surgery after a 6–8 week interval.
This CRT consisted of radiation in 28 fractions of
1.8 Gy, on weekdays combined with oral capecitabine
(825 mg/m2, twice a day for 7 days a week), or capecit-
abine with oxaliplatin (oxaliplatin 130 mg/m2 on day
one) in patients with synchronous distant metastases.
Patients underwent surgery 6–8 weeks after the last frac-
tion of radiation therapy. One to two weeks before sur-
gery patients underwent a new pelvic MRI, to evaluate
local status as a roadmap for surgery.
Surgery consisted of a low anterior resection or
abdominoperineal resection (APR) according to the
TME-principle as described by Heald.18 All surgeons
were trained in high quality TME surgery as a result
of the widespread implementation of TME after the
results of the Dutch TME trial in The Netherlands. In
selected cases of early tumours a local excision (snare
polypectomy or transanal endoscopic microsurgery)
was performed. For locally advanced tumours, the
extent of the resection was based on the MR images.
For large tumours the TME sometimes had to betratiﬁcation scheme.
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resection of surrounding organs when required. Adju-
vant chemotherapy was generally considered for all
locally advanced tumours treated with CRT and for
tumours with involved nodes at histology. Chemother-
apy consisted of 6 courses of oral capecitabine
(1000 mg/m2 twice daily during 2 weeks) with intrave-
nous oxaliplatin 130 mg/m2 at day 1, or capecitabine
(1000 mg/m2) as monotherapy.2.7. Histological evaluation
The resection specimen was evaluated in a standard-
ised way, as described by Quirke.19 A complete resection
(R0) was deﬁned as a circumferential resection margin
of P1 mm. For the patients who underwent local exci-
sion, a complete resection of the tumour at histology
as well as a conﬁrmed N0 status at follow-up MRI
was considered a complete resection.2.8. Follow-up
Follow-up after treatment for rectal cancer followed
the national guidelines: clinical examination every
6 months for the ﬁrst 3 years, and yearly until 5 years
of follow-up, carcinoembryonic antigen (CEA) measure-
ments every 3 months for the ﬁrst 3 years, and every
6 months until 5 years of follow-up and liver ultrasonog-
raphy or CT-scan twice yearly in the ﬁrst year and
yearly thereafter until 5 years of follow-up. For those
patients who underwent a local excision, follow-up
MRI was performed at least after 6 months and 1 year,
in addition to endoscopic follow-up. Local recurrence,
distant recurrence, death or event-free interval from
the day of surgery were scored for all patients.2.9. Comparison with Dutch TME trial
Three-year survival data and the number of complete
resections were compared to the individual data of the
Dutch TME trial that were provided by the Dutch
TME trial group. This was considered as the best avail-
able comparison as it is a large prospective database in
the setting of a randomised controlled trial and reﬂects
the outcome of patients with rectal cancer before the
widespread use of MRI. The setting for the Dutch
TME trial was comparable to the set-up of the current
cohort study and the inclusion and exclusion criteria
are very similar. Patients who were in a palliative setting
were excluded from the Dutch TME trial. A diﬀerence in
selection criteria between both studies is that the present
study includes all comers, including the very early
tumours and the very locally advanced tumours,
whereas the Dutch TME trial did not include these
two groups. The main diﬀerence between the two studies
was that local staging with MRI was not mandatory inthe Dutch TME trial, and was performed only in a
minority of patients.6 Because of the small but real dif-
ference in patient population the outcome results were
compared without formal statistical comparison.2.10. Statistical analysis
Baseline characteristics were prospectively collected.
Postoperative course and complications were scored
using the Dindo classiﬁcation.20 For the estimation of
long term outcome Kaplan Meier survival functions
were used. Local control was deﬁned as the absence of
pelvic recurrence; distant-metastasis free survival as
the absence of distant metastasis outside the pelvis; dis-
ease-free survival as the absence of a local and distant
recurrence and death from cancer-related cause; and
overall survival as the absence of death from any cause.
The chi-square test was used for comparison of propor-
tions. All statistical analyses were performed using Sta-
tistical Package for the Social Sciences (SPSS) (version
16.0; SPSS, Chicago, IL) and STATA 11.0.3. Results
Overall 296 patients were included. Of these patients,
13 were not evaluable because of MRI-related problems
(artefacts, refusal) (n = 5) and refusal of treatment
(n = 8). Of the remaining 283 patients ﬁve had a previ-
ous malignancy, one had a coexisting malignancy and
47 were not treated with a curative intent because of
widespread unresectable metastatic disease (n = 46)
and because of very poor general condition (n = 1).
Therefore, 230 patients could be included for this
study. Sixteen of these patients presented with synchro-
nous metastatic disease that was considered potentially
curable. For these patients the three-year survival esti-
mates are reported separately. Of the 230 included
patients 134 (58%) were male. Mean age (±standard
deviation (SD)) was 67 (±10.6) years.
In 31 patients the actual treatment diﬀered from the
MRI based proposal. This was most often due to
advanced age or poor condition of the patient, illus-
trated by 20 patients with a locally advanced tumour
on MRI who were treated with 5  5 Gy (n = 18) or sur-
gery only (n = 2). In seven patients surgery without
radiotherapy was chosen whereas MRI advised short
course radiotherapy and four patients received a short
course of radiotherapy whereas MRI advised surgery
only. Fig. 2 shows the stratiﬁcation of the actual
received treatment.3.1. Surgery and perioperative period
Twenty-one patients underwent a local excision, 134
a low anterior resection (11 of which with an extended
TME), 71 an APR (25 ‘extended’), one patient a total
Table 1
Dindo classiﬁcation of surgical complications.
All patients, n = 228
No complications 46% (105/228)
Grade I 18% (40/228)
Grade II 10% (22/228)
Grade III A/B 20% (46/228)
Grade IV A/B 2% (5/228)
Grade V 4% (10/228)
Surgical complications according to Dindo et al.:
grade I: any deviation from normal postoperative
course that does not require treatment other than
antiemetics/analgetics; grade II: complications
requiring pharmacological treatment, e.g. urinary
tract infection; grade III: complications requiring
surgical/endoscopic/radiological intervention, (A)
without general anaesthesia or (B) with general
anaesthesia; grade IV: Life threatening complications
requiring ICU admission, (A) with single organ dys-
function or (B) with multiorgan dysfunction; grade V:
complications leading to death of the patient.
Fig. 2. Flow diagram of actual received treatment.
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exenteration. Furthermore, two patients had a clinical
complete response to CRT, conﬁrmed by repeated biop-
sies and imaging. These patients preferred not to
undergo surgery and are currently in a follow-up proto-
col. They were not included in the analysis for complete
resections but were included in the analysis of long-term
outcome.
All local excisions (n = 21) were performed during a
short hospital stay of 2–3 days (TEM) or in the outpa-
tient clinic (snare polypectomy) and were uncompli-
cated. For the other patients (n = 207), median
hospital stay was 11 days (range: 4–199). There were
123 patients having one or more post-operative compli-
cations. The severity of the complications is graded
using the Dindo-classiﬁcation20 in Table 1.
As shown in Table 1, 10 patients died postoperatively
during their initial hospital stay (Dindo grade V), six of
whom within 30 days. The postoperative mortality of all
patients (including local excision) is 4.3% with a 30-days
mortality of 2.6%. In four patients death was directly
related to surgical complications, the other six patients
died of (often multiple) systemic postoperative compli-
cations (e.g. myocardial infarction).3.2. Histological examination
The number of complete resections and the distribu-
tion in the diﬀerent stages at histopathological examina-
tion after surgery are shown in Table 2. The number of
complete resections of 95.6% is much higher than the
84.1 in the Dutch TME trial (unpublished data). The
number of complete resections did not diﬀer signiﬁ-
cantly between the treatment groups in the present trial
(p = 0.201). An involved margin after surgery was seenin 4.4% of patients (n = 10), and was due to (a combina-
tion of) (1) failure in surgical technique: tumour perfora-
tion during surgery (n = 5) or incomplete removal of the
entire mesorectum, and/or (2) surgical planning (n = 8):
insuﬃcient attention to MR images after CRT by the
surgeon, showing a margin that was still at risk. In none
of these patients the cause of the incomplete resection
could be traced to an underestimation of the circumfer-
ential resection margin on MRI as described by the radi-
ologist. The incomplete resections are summarised in
Table 3.3.3. Adjuvant chemotherapy
Adjuvant chemotherapy was administered to all
patients who had primary synchronous metastasis (7%,
16/230). In the other patients who were treated with
curative intent adjuvant chemotherapy was adminis-
tered in 19% of patients treated with surgery only, in
20% of patients treated with 5  5 Gy and surgery and
in 60% of the patients treated with CRT and surgery.3.4. Follow-up
The median follow-up was 41 (0–83) months. The
three-year local recurrence rate was 2.2% (95% C.I.;
0.8–5.7%) for all patients (Fig. 3), as compared to
6.2% (95% C.I. 5.1–7.6%) from the individual data of
the Dutch TME trial. The seven patients who developed
a local recurrence are summarised in Table 4. None of
the local recurrences occurred in the group of patients
with an incomplete resection.
Three-year distant-metastasis-free survival, disease-
free survival and overall survival were 85.5% (95%
C.I.; 80–90%), 80.2% (74–85%) and 84.5% (79–89%),
respectively (see Fig. 3). Three-year survival estimates
Fig. 3. Local recurrence-free, distant-metastasis-free, disease-free and overall survival curves of all patients treated with curative intent that did not
have primary metastases at presentation.
Table 3
Characteristics of patients with incomplete resections.
Patient Treatment Distance anal verge (cm) (y)pTNcM CRM involvement LR DR DR time Status OS time
1 5  5 Gy + LAR 7 T3N0M0 +   n.a. NED 43
2 5  5 Gy + APR 0 T3N0M0 +   n.a. NED 38
3 CRT + APR 0 T3N1M0 +  + 13 DOD 18
4 CRT + APR 0 T2N0M0 +  + 29 AWD 54
5 CRT + LAR 2 T3N1M0 +   n.a. NED 36
6 CRT + APR 7 T3N0M0 +   n.a. NED 55
7 CRT + APR 3 T3N0M0 +  + 10 DOD 38
8 CRT + LAR 3 T3N0M1    n.a. NED 48
9 5  5 Gy + APR 0 T3N1M0 +   n.a. DOC 32
10 5  5 Gy + LAR 3 T3N0M0    n.a. DOD 0
Gy = Gray; LAR = low anterior resection; APR = abdominoperineal resection; CRT = chemoradiation; CRM = circumferential resection mar-
gin; LR = local recurrence; DR = distant recurrence; NED = no evidence of disease; DOD = death of disease; AWD = alive with disease;
DOC = death of other causes; OS = overall survival.
Table 2
Number of complete resections and distribution of American Joint Committee on Cancer (AJCC) stage at histology.
N R0 (%) 0 I II III IV
Local excision/total mesorectal excision (TME) 49/49 (100) 0 34 6 9 0
5  5 Gy (Gray) + TME 82/86 (95.3) 0 29 28 23 6
Chemoradiation (CRT) + surgerya,b 87/93 (93.5) 14 22 23 24 10
Total 218/228 (95.6) 14 85 57 56 16
a AJCC stage for these patients is stage after neoadjuvant therapy: ypTNM.
b 2/95 Patients of the CRT + surgery refused surgery after CRT and were therefore left out of the analysis of complete resections.
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with curative intent were 16% (3–40%), 13% (2–35%)
and 44% (20–66%), respectively.
The Dutch TME trial shows a three-year distant-
metastasis-free, disease-free and overall survival of
79.1% (95% C.I.; 77–81%), 76.8% (75–79%) and 81%
(79–83%) respectively. Given the fact that in the Dutch
TME trial locally very advanced tumours were excluded
whereas they were included in the present study, there is
a suggestion that the overall results have improved with
the current MRI based strategy.4. Discussion
This study shows that tailored treatment of primary
rectal cancer based on preoperative MR imaging leads
to a high rate (95.6%) of complete resections and an
excellent three-year local control with a local recurrence
rate of only 2.2%. Overall survival was 84.5%.
The number of complete resections is much better
than older series on rectal cancer treatment, and much
better than the 84.1% in the Dutch TME trial. The
2.2% local recurrence rate also compares favourably
with 3.4% of the 5  5 Gy radiation group in the Dutch
TME trial21 and 4.4% at 3 years in the MRC CR07
trial.22 In the trials on neoadjuvant CRT for locally
advanced tumours the 5 year local recurrence rates were
7.6% (Bosset et al.) and 6% (Sauer et al.).2,3 A strict
comparison is however diﬃcult as many series and ran-
domised trials focus on a well-deﬁned group of patients
with rectal cancer whereas the present study includes ‘all
comers’ without any selection. It is important to realise
that the good results of the current study may be related
to a number of recent improvements in the treatment of
rectal cancer. In the Dutch TME trial, which ran from
1996 to 1999, a special emphasis was placed on quality
assurance of surgical TME technique. With workshops,
videos, visits of renowned rectal surgeons and a system
of continued proctoring the TME technique became
standard in most surgical practices. Additionally, up-
to-date high resolution MR techniques were standard
in the current study. MRI shows the proximity of the
tumour to the important surgical planes in distal rectal
cancer, and helps the surgeon to perform a complete
resection.23 MRI also identiﬁes tumours that invade or
come close to the mesorectal fascia, tumours that are
best treated with a long course of neoadjuvant CRT
rather than a short course of radiotherapy. The Mercury
Study, a multicentre prospective study that used an
MRI based selection similar to the present study,
reported a 5 year local recurrence rate of 3.3% for the
subgroup of patients (33% of the entire cohort) with a
good prognosis who were treated without neoadjuvant
therapy, with an overall and disease free survival of
68% and 85% respectively.24 Although the MR based
selection in the Mercury study was similar to our study,their treatment policy that followed this selection was
much more restricted regarding the use of neoadjuvant
therapy. In the Mercury study only 32% of patients
received neoadjuvant therapy compared to 78% in our
study.25 The overall long term outcome results of the
Mercury study have not yet been published, and it
would be interesting to compare the local recurrence
rates of these two policies. Another factor that may have
contributed to the good outcome in the current study is
the important role in the decision making process of the
multidisciplinary team, a factor that is considered to be
essential in modern rectal cancer treatment.26–284.1. Positive margins
An interesting and puzzling ﬁnding in this study is the
fact that none of the patients with a positive margin at
histology developed a local recurrence. A recent review
conﬁrmed the earlier observations that a positive margin
is a risk factor for local recurrence, even more so when
patients are treated with neoadjuvant CRT.29,30 The fact
that this is not observed in the present study could be
just a chance observation, or be caused by a too short
follow-up time. The strategy in the present study was
speciﬁcally aimed at avoiding a positive margin, making
optimal use of MRI, sound surgical technique and with
liberal use of CRT for tumours close to the mesorectal
fascia and for very distal tumours. Maybe the few
tumours with positive margins that result from such a
strategy are diﬀerent from the tumours with positive
margins in older series with a much higher rate of
incomplete resections. It is therefore unclear whether a
positive margin can still be used as a surrogate end-point
for local recurrence.
APRs in rectal cancer surgery are often associated
with a higher percentage of incomplete resections and
an adverse outcome.31 Presently, a wide cylindrical
APR for distal rectal cancer is therefore advocated in lit-
erature,32,33 as it would increase the chance for a com-
plete resection. However, in this study a cylindrical
resection for distal rectal tumours was not performed
routinely, without apparently compromising outcome,
although there were more incomplete resections in the
APR group as shown in Table 3. Neoadjuvant CRT
as well as dedicated MR imaging as a roadmap to the
surgeon might again be responsible for this result. It is
also in line with the retrospective analysis of Messenger
et al.34 in which similar incomplete resection and local
recurrence rate were found as compared to studies advo-
cating a wide cylindrical excision, in a group of patients
in which >50% received neoadjuvant CRT.
This multicentre cohort study of unselected consecu-
tive rectal cancer patients illustrates the morbidity and
mortality that is associated with rectal cancer surgery.
One out of ﬁve patients required an intervention after
initial surgery, ranging from drainage of an abscess to
Table 4
Characteristics of patients who developed a local recurrence.
Patient Treatment Distance anal verge
(cm)
R0/
R1
(y)pTNcM LR
time
Treatment of
recurrence
DR DR
time
Status OS
time
1 5  5 Gy + LAR 12 R0 T3N0M1 36  + 10 DOD 45
2 Local excision 15 R0 T1N0M0 42 LAR  n.a. NED 52
3 CRT + APR 0 R0 T3N0M0 21 Surgery  n.a. NED 33
4 Local excision 4 R0 T1N0M0 3 LAR + 4 AWD 32
5 LAR 9 R0 T3N1M0 20 Surgery + 40 AWD 57
6 CRT + APR 0 R0 T3N2M0 9  + 9 DOD 18
7 5  5 Gy + LAR 9 R0 T1N0M0 48 Surgery  n.a. NED 50
Gy = Gray; LAR = low anterior resection; APR = abdominoperineal resection; CRT = chemoradiation; R0 = complete resection; R1 = incom-
plete resection; LR = local recurrence; DR = distant recurrence; NED = no evidence of disease; DOD = death of disease; AWD = alive with
disease; OS = overall survival.
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overall postoperative mortality is 4%. Old patients and
patients with severe comorbidity were often treated with
the short course radiotherapy (n = 20) or even no radio-
therapy at all (n = 7) despite the presence of risk factors
for local recurrence, because CRT was considered too
toxic. This bias or ‘confounding by indication’ can
explain the higher mortality in the short-course radio-
therapy group as compared to the CRT group.
In addition to short-term morbidity, multimodal rec-
tal cancer treatment is also associated with long term
functional morbidity. This study did not assess the def-
ecation and urogenital long term function. Undoubtedly
the very low local recurrence rate had been achieved at
the cost of functional long term morbidity. We have
the feeling that many patients have been ‘overtreated’
with neoadjuvant therapy, and the question is still open
how to ﬁnd the optimal balance between local control
and good functional outcome.
4.2. Improving survival
Multidisciplinary eﬀorts to obtain a good local con-
trol of rectal cancer have paid oﬀ well. However, many
patients still die of metastatic disease. In the present
cohort 21% of patients at primary diagnosis presented
with metastases, and 15% of the remaining patients
developed metastatic disease at a later stage. Unfortu-
nately only a minority of these patients are ultimately
cured, despite aggressive multimodal treatment. Earlier
detection of metastatic disease, more active systemic
therapy and a more individualised approach using pre-
dictive factors could improve not only disease control,
but also long term survival, especially when combined
with metastasectomies. There is a new tendency to
address the metastatic disease simultaneously with the
primary tumour or even before the primary tumour,
reﬂected in neoadjuvant systemic therapy protocols
and in the surgical ‘liver ﬁrst approach’ in which meta-
static disease is resected before the primary tumour.35
A major step forward in improving colorectal cancer
survival is expected from large screening programs, thatnot only lower the overall incidence of colorectal cancer
but also the proportion of advanced tumours.36,37
4.3. Limitations of the study
The main limitation of this study is that, in contrast
to a randomised study, a cohort study cannot provide
solid proof that a diﬀerentiated approach leads to a bet-
ter outcome than a more uniform treatment schedule.
Besides accurate and high quality MR imaging other
factors contributed to our good outcome: improved
TME surgery and multidisciplinary treatment. The pri-
mary aim of this study was, however, to evaluate the
outcome of an MRI based treatment approach in this
setting of high quality TME and multidisciplinary treat-
ment. The study shows that with this approach in our
setting an excellent local control can be achieved,
although we cannot exclude that other factors could
play a role too. Another limitation is a relatively short
median follow-up of 3 years. Although 3 years is a
well-accepted end-point in oncological research, late
recurrences can occur after neoadjuvant CRT. A further
limitation of the study is the practical diﬃculty of MR
staging with the lymph node speciﬁc contrast agent
USPIO, an agent that is no longer available on the mar-
ket despite promising initial results.14,15 Although with
standard MR imaging without USPIO the accuracy of
the predicted nodal status will be slightly lower, the
key features in the MR stratiﬁcation scheme – mesorec-
tal fascia invasion, T-stage and tumour height will be
equally accurate. Recent literature shows that there is
a continued search for good lymph node contrast
agents.38
5. Conclusion
With a diﬀerentiated multimodality treatment based
on dedicated preoperative MR imaging, local recurrence
is no longer the main problem in rectal cancer treatment.
The new challenges are early diagnosis and treatment,
reducing morbidity of treatment and prevention and
treatment of metastatic disease.
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